SynthesisEuropean journal of clinical pharmacology1997

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

P M Christensen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.